Cardiology-Heart Failure

Title: Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
Description: The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).
Drug/Procedure: BAROSTIM NEO® System (Device)
NCT Number: 02627196
Notes:  
Start Date: 6/30/17
Status: Recruiting
Principal Name: Ilyas Colombowala, MD 
Contact Name: Jennifer Yehle, CRC
Phone: (208)302-0066